Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242094 | 1.00 | OPRK1 (0.49) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL4614574 | 0.87 | SLC6A3 (0.49) | OPRK1OPRD1KMT2AOPRM1HSD11B1 | |
| SCHEMBL16422536 | 0.87 | SLC6A3 (0.49) | OPRK1OPRD1KMT2AOPRM1HSD11B1 | |
| SCHEMBL4666335 | 0.87 | SLC6A3 (0.49) | OPRK1OPRD1KMT2AOPRM1HSD11B1 | |
| SCHEMBL6042399 | 0.87 | KMT2A (0.49) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL18038731 | 0.83 | OPRL1 (0.59) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL28063989 | 0.82 | OPRK1 (0.56) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL2925713 | 0.82 | CNR2 (0.53) | OPRK1OPRD1KMT2AMEN1OPRL1 | |
| SCHEMBL20820421 | 0.81 | ALK (0.49) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL2239220 | 0.81 | ALK (0.49) | OPRK1OPRD1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1928460-A2 | MC4R-AGONISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | Pfizer Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015157-A2 | MC4R-AG0NISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | OPRK1 24/4885OPRD1 8/4885ALDH1A1 590/4885 |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | OPRK1 543/4885OPRD1 308/4885ALDH1A1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.